{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:03:58Z","timestamp":1770887038835,"version":"3.50.1"},"reference-count":64,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13079","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:01:08Z","timestamp":1769601668000},"page":"1-22","source":"Crossref","is-referenced-by-count":0,"title":["Effect of SGLT2 inhibitors on heart failure outcomes in patients with and without diabetes: A systematic review and meta\u2011analysis of randomized controlled trials"],"prefix":"10.3892","volume":"31","author":[{"given":"Duaa","family":"Bafail","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noura","family":"Alhalees","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Drug Information, King Abdullah Medical Complex, Ministry of Health, Jeddah 23816, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"key20260212100656_b1-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"key20260212100656_b2-ETM-31-3-13079","first-page":"965","article-title":"Pathophysiology of heart failure, hemodynamic changes and their consequences","volume":"4","author":"Sheraliev","year":"2025","journal-title":"Mod Sci Res"},{"issue":"16","key":"key20260212100656_b3-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00728-8","article-title":"Global, regional, and national burden of heart failure and its underlying causes, 1990-2021: Results from the global burden of disease study 2021","volume":"13","author":"Ran","year":"2025","journal-title":"Biomark Res"},{"key":"key20260212100656_b4-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10741-022-10282-2","article-title":"Right ventricular failure in left heart disease: From pathophysiology to clinical manifestations and prognosis","volume":"28","author":"Dini","year":"2023","journal-title":"Heart Fail Rev"},{"key":"key20260212100656_b5-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11897-017-0328-x","article-title":"Pharmacological and non-pharmacological treatment for decompensated heart failure: What is new?","volume":"14","author":"Shah","year":"2017","journal-title":"Curr Heart Fail Rep"},{"issue":"e11","key":"key20260212100656_b6-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: An updated review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card Fail Rev"},{"issue":"82","key":"key20260212100656_b7-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: A review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"issue":"695792","key":"key20260212100656_b8-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695792","article-title":"The diabetic cardiomyopathy: The contributing pathophysiological mechanisms","volume":"8","author":"Salvatore","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"key20260212100656_b9-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02042-9","article-title":"Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: A systematic review and meta-analysis","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"key20260212100656_b10-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/IJNRD.S268811","article-title":"SGLT2 inhibitors: Emerging roles in the protection against cardiovascular and kidney disease among diabetic patients","volume":"13","author":"Vasquez-Rios","year":"2020","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"key20260212100656_b11-ETM-31-3-13079","author":"Singh"},{"key":"key20260212100656_b12-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart rhythm"},{"issue":"1046194","key":"key20260212100656_b13-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1046194","article-title":"Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis","volume":"10","author":"Treewaree","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"key20260212100656_b14-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The dapagliflozin and prevention of Adverse-outcomes in heart failure (DAPA-HF) trial: Baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"key20260212100656_b15-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"e245135","key":"key20260212100656_b16-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5135","article-title":"SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: A systematic review and meta-analysis","volume":"7","author":"Gao","year":"2024","journal-title":"JAMA Netw Open"},{"key":"key20260212100656_b17-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/cvr\/cvab271","article-title":"Cardiovascular effects of non-insulin glucose-lowering agents: A comprehensive review of trial evidence and potential cardioprotective mechanisms","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc Res"},{"key":"key20260212100656_b18-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ihj.2023.03.003","article-title":"SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis","volume":"75","author":"Banerjee","year":"2023","journal-title":"Indian Heart J"},{"issue":"765","key":"key20260212100656_b19-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-05127-3","article-title":"The role of SGLT 2 inhibitors in heart failure with preserved ejection fraction (HFpEF): A systematic review and Meta-analysis of randomized controlled trials","volume":"25","author":"Minisy","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"issue":"e934475","key":"key20260212100656_b20-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.934475","article-title":"Review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci Monit"},{"key":"key20260212100656_b21-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Syn Methods"},{"key":"key20260212100656_b22-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.euf.2023.10.014","article-title":"Evaluating the certainty of evidence in Evidence-based medicine","volume":"9","author":"Gonz\u00e1lez-Padilla","year":"2023","journal-title":"Euro Urol Focus"},{"key":"key20260212100656_b23-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"key20260212100656_b24-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: The CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"key":"key20260212100656_b25-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/ejhf.3292","article-title":"Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"key20260212100656_b26-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"key20260212100656_b27-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ejhf.3548","article-title":"Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial","volume":"27","author":"Petrie","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"key20260212100656_b28-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260212100656_b29-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/dom.14015","article-title":"Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"key20260212100656_b30-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260212100656_b31-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260212100656_b32-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"key20260212100656_b33-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260212100656_b34-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"key20260212100656_b35-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial","volume":"105","author":"Inzucchi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"key20260212100656_b36-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"key20260212100656_b37-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"key20260212100656_b38-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"key20260212100656_b39-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/dom.13920","article-title":"Clinical outcomes with canagliflozin according to baseline body mass index: Results from post hoc analyses of the CANVAS Program","volume":"22","author":"Ohkuma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"key20260212100656_b40-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"key20260212100656_b41-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"key20260212100656_b42-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"key20260212100656_b43-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: Results from the EMPEROR-Reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"key20260212100656_b44-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: Insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"key20260212100656_b45-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: Results From the EMPULSE trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"key":"key20260212100656_b46-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"key20260212100656_b47-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin versus placebo on symptoms and 6-Minute walk distance in patients with heart failure: The DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"key":"key20260212100656_b48-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"Eur Heart J"},{"key":"key20260212100656_b49-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure","volume":"9","author":"McMurray","year":"2021","journal-title":"JACC Heart failure"},{"key":"key20260212100656_b50-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"key20260212100656_b51-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: A systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"e019463","key":"key20260212100656_b52-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of Sodium\/Glucose Cotransporter 2 (SGLT2) Inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: A systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"key20260212100656_b53-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1001\/jama.2021.20739","article-title":"Contextualizing risk among patients with heart failure","volume":"326","author":"Greene","year":"2021","journal-title":"JAMA"},{"key":"key20260212100656_b54-ETM-31-3-13079","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus: Impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"key20260212100656_b55-ETM-31-3-13079","author":"Kluger"},{"key":"key20260212100656_b56-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.2337\/dc18-2515","article-title":"Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction","volume":"42","author":"Tromp","year":"2019","journal-title":"Diabetes Care"},{"key":"key20260212100656_b57-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"key20260212100656_b58-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"615","DOI":"10.14740\/jocmr3467w","article-title":"SGLT-2 inhibitors and cardiovascular protection: Lessons and gaps in understanding the current outcome trials and possible benefits of combining SGLT-2 Inhibitors With GLP-1 agonists","volume":"10","author":"Abdelgadir","year":"2018","journal-title":"J Clin Med Res"},{"key":"key20260212100656_b59-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"key20260212100656_b60-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"issue":"4125","key":"key20260212100656_b61-ETM-31-3-13079","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30204125","article-title":"Sodium-Glucose Cotransporter-2 inhibitors in diabetes and beyond: Mechanisms, pleiotropic benefits, and clinical Use-Reviewing protective effects exceeding glycemic control","volume":"30","author":"Hanke","year":"2025","journal-title":"Molecul"},{"issue":"29","key":"key20260212100656_b62-ETM-31-3-13079","article-title":"SGLT2 inhibitors across various patient populations in the era of precision medicine: The multidisciplinary team approach","volume":"3","author":"McLean","year":"2025","journal-title":"npj Metab Health Dis"},{"key":"key20260212100656_b63-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.hfc.2022.03.006","article-title":"SGLT2 inhibitors in heart failure with reduced ejection fraction: A paradigm shift toward dual Cardio-renal protection","volume":"18","author":"Rastogi","year":"2022","journal-title":"Heart Fail Clin"},{"key":"key20260212100656_b64-ETM-31-3-13079","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11906-024-01314-3","article-title":"Is there a role for SGLT2 inhibitors in patients with end-stage kidney disease?","volume":"26","author":"Siddiqui","year":"2024","journal-title":"Curr Hypertens Rep"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:07:03Z","timestamp":1770883623000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,28]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13079","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}